Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
9.59
-0.14 (-1.44%)
Dec 20, 2024, 4:00 PM EST - Market closed
Theravance Biopharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for TBPH stock have an average target of 13.75, with a low estimate of 9.00 and a high estimate of 21. The average target predicts an increase of 43.38% from the current stock price of 9.59.
Analyst Consensus: Buy
* Price targets were last updated on Sep 16, 2024.
Analyst Ratings
The average analyst rating for TBPH stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +56.41% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $15 | Strong Buy | Maintains | $20 → $15 | +56.41% | Aug 6, 2024 |
| TD Cowen | TD Cowen | Hold Maintains $10 → $9 | Hold | Maintains | $10 → $9 | -6.15% | Aug 6, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $15 → $10 | Buy → Hold | Downgrades | $15 → $10 | +4.28% | Aug 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +108.55% | May 29, 2024 |
Financial Forecast
Revenue This Year
63.97M
from 57.42M
Increased by 11.41%
Revenue Next Year
87.88M
from 63.97M
Increased by 37.36%
EPS This Year
-1.08
from -1.00
EPS Next Year
0.11
from -1.08
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 67.4M | 98.9M | 142.0M | |||
| Avg | 64.0M | 87.9M | 100.8M | |||
| Low | 59.4M | 75.2M | 70.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 17.4% | 54.5% | 61.5% | |||
| Avg | 11.4% | 37.4% | 14.7% | |||
| Low | 3.4% | 17.5% | -19.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.03 | 0.69 | 1.12 | |||
| Avg | -1.08 | 0.11 | -0.09 | |||
| Low | -1.18 | -0.60 | -1.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 935.7% | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.